Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90

Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital

April 29, 2016 7:57 AM EDT

BMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $183.00). He notes while results were solid all eyes will be on the upcoming Repatha CV outcomes trial.

Somaiya commented, "AMGN... More

Amgen (AMGN) PT Raised to $186 at Leerink Partners

April 29, 2016 6:58 AM EDT

Leerink Partners analyst Geoffrey Porges raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $179.00) following solid Q1 results but stopped short of upgrading the stock and maintained an Market Perform rating.

Porges commented, "Revenue of $5.527bn handily beat consensus by 5%, although it fell short of our estimate of $5.66bn by 2% (Exhibit 1). The main drivers of the revenue... More